The FDA said that giving the recalled drug to patients with a lidocaine allergy could cause a potentially life-threatening allergic reaction. No adverse events have been reported, the drugmaker said Nov. 19.
Fresenius Kabi is asking its customers to check their stock immediately and quarantine any of the affected product.
Read the full news release here.
More articles on pharmacy:
Eli Lilly’s arthritis drug gets emergency approval as COVID-19 treatment
Pfizer applies for COVID-19 vaccine emergency approval
WHO: Stop giving COVID-19 patients remdesivir
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.